The suit calls into focus one of the central issues at play: whether Mr. Ackman improperly built up his nearly 10 percent stake in Allergan as he prepared to make a bid with Valeant for Allergan.

from DealBook» Mergers & Acquisitions http://ift.tt/1tDaea2
via IFTTT

Publicités